Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04XVE
|
|||
Former ID |
DIB003445
|
|||
Drug Name |
QAX-028
|
|||
Synonyms |
Bronchodilatory agent (inhaled, COPD), Novartis
Click to Show/Hide
|
|||
Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 2 | [1] | |
Company |
Novartis AG
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Muscarinic acetylcholine receptor (CHRM) | Target Info | Antagonist | [2] |
KEGG Pathway | Calcium signaling pathway | |||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
PI3K-Akt signaling pathway | ||||
Cholinergic synapse | ||||
Regulation of actin cytoskeleton | ||||
Pathwhiz Pathway | Muscle/Heart Contraction | |||
Reactome | Muscarinic acetylcholine receptors | |||
Acetylcholine regulates insulin secretion | ||||
G alpha (q) signalling events | ||||
WikiPathways | Monoamine GPCRs | |||
Calcium Regulation in the Cardiac Cell | ||||
Regulation of Actin Cytoskeleton | ||||
GPCRs, Class A Rhodopsin-like | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Secretion of Hydrochloric Acid in Parietal Cells | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01068613) Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health. | |||
REF 2 | EP patent application no. 2398798, Triazolopyridine derivatives as p38 map kinase inhibitors. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.